The topic of biologic therapy for IBD has been selected for this Focus issue of Nature Reviews Gastroenterology & Hepatology because of the important implications it has for disease management.

If you have an inflammatory bowel disease like Crohn’s or ulcerative colitis and have trouble focusing or remembering things, ...

Analysts have suggested that TL1A inhibitors could have blockbuster sales potential as second-line therapy for IBD refractory to first-line TNF biologics, with plenty of upside if they move into ...

"Our study suggests that vedolizumab is a viable option for induction and long-term maintenance therapy in children with IBD, ...

High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118 , 279–288 (2000). Article CAS PubMed Google Scholar ...

combination therapy, observation or novel dietary or microbial interventions. Created with BioRender.com. IBD, inflammatory bowel disease. Credit must be given to the creator.

upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel disease, joining a race to bring the first drug in the class to market. Sanofi has acquired rights to co ...

As for tolerability, the companies said the experimental therapy was well tolerated with no safety signals. The duo has planned a Phase 3 program for the drug in IBD, subject to regulatory feedback.

U.S. News released its list of best diets for 2025: the low-FODMAP diet landed on top for irritable bowel syndrome and the ...

"The PREDICT-UC study potentially signals the end of accelerated or intensified dosing strategies for infliximab as rescue therapy for acute severe ulcerative colitis, which should prompt new ...